Neurodevelopmental outcome of children exposed to pravastatin in utero
Researchers from the Eunice Kennedy Shriver National Institute of Child Health and Human Development-Obstetrics Fetal Pharmacology Research Centers Network have conducted a long-term follow-up study to determine the impact pravastatin treatment in pregnant women at high risk of preeclampsia may have on child health, growth, and neurodevelopment. The results of this small study, although limited by the trial’s sample size (n=40 exposed children), did not identify any long-term neurodevelopmental safety signal for pravastatin. More information can be found here.
Photo by Mufid Majnun on Unsplash